Priveterra Acquisition Corp.
Completed 2023-07-21- CIK 1837607
- PMGM
- Now AEON
- IPO 2021-02-11
- $21.2M trust
- 357 filings
Successfully merged with AEON Biopharma, Inc. • Now trading as AEON
- IPO Size
- $276M
- raised at the IPO
- Trust
- $21.2M
- as of 2023-06-30
- Current Status
- Completed
- from its latest filing
- IPO Year
- 2021
- year it listed
Filings, by quarter
357 filings over 25 quarters; violet bars carry a milestone
- 20 Q4: 1 filing
- 21 Q1: 18 filings
- 21 Q2: 4 filings
- 21 Q3: 1 filing
- 21 Q4: 1 filing
- 22 Q1: 6 filings
- 22 Q2: 1 filing
- 22 Q3: 2 filings
- 22 Q4: 12 filings
- 23 Q1: 24 filings
- 23 Q2: 39 filings
- 23 Q3: 42 filings
- 23 Q4: 10 filings
- 24 Q1: 18 filings
- 24 Q2: 27 filings
- 24 Q3: 28 filings
- 24 Q4: 6 filings
- 25 Q1: 22 filings
- 25 Q2: 31 filings
- 25 Q3: 4 filings
- 25 Q4: 10 filings
- 26 Q1: 18 filings
- 26 Q2: 16 filings
- 26 Q3: 15 filings
- 26 Q4: 1 filing
- S-1 filed 20 Q4
- IPO 21 Q1
- Definitive agreement 22 Q4
- Completed 23 Q3
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
Priveterra Acquisition Corp. is a blank-check company formed to merge with, acquire, or otherwise combine with one or more businesses. It intends to focus on a medical technology company in the healthcare industry, although it may pursue opportunities in any industry or sector.
Investment Focus
Healthcare
Key Information
As the filings state it
- IPO Date
- 2021-02-11
- Total Redemptions
- $274M
- PIPE
- $7M
- Jurisdiction of Incorporation
- Delaware
- SIC
- 6770
- Completion Date
- 2023-07-21
- Merger Target
- AEON Biopharma, Inc.
- SPAC Ticker
- PMGM
- Merged Ticker
- AEON
Stock Performance
AEONTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2023-01-03 | $10.06 | |
| At Merger | 2023-07-24 | $9.20 | -9% |
| 6 Months Post-Merger | 2024-01-22 | $8.10 | -12% |
| 1 Year Post-Merger | 2024-07-22 | $2.35 | -74% |
| 2 Years Post-Merger | 2025-07-21 | $0.81 | -91% |
| Current Price | 2026-10-16 | $0.23 | -98% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The team is led by Robert Palmisano, Vikram Malik, Oleg Grodnensky and David Meredith. Their stated experience includes executive leadership, investment banking, healthcare and medical-technology operations, M&A, finance, and legal work.